title: Targeting PIM kinase activity significantly augments the efficacy of cytarabine.
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Kelly
authors.forename: Claudia M
authors.initials: CM
authors.lastname: Espitia
authors.forename: Pietro
authors.initials: P
authors.lastname: Taverna
authors.forename: Gavin
authors.initials: G
authors.lastname: Choy
authors.forename: Swaminathan
authors.initials: S
authors.lastname: Padmanabhan
authors.forename: Steffan T
authors.initials: ST
authors.lastname: Nawrocki
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Giles
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Carew
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D003561:Cytarabine / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D051573:Proto-Oncogene Proteins c-pim-1 / Q000037:antagonists & inhibitors*; D011724:Pyridazines / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545188:SGI 1776; D003561:Cytarabine; D051573:Proto-Oncogene Proteins c-pim-1; C406031:proto-oncogene proteins pim